Peter Attia's Longevity Transformation Timeline: From Surgeon to Medicine 3.0 Pioneer

Who Is Peter Attia?

Peter Attia is a Canadian-American physician who trained in general surgery at Johns Hopkins Hospital before spending two years at the National Cancer Institute applying quantitative methods to immunotherapy research. He left academic surgery in the early 2010s, a decision he has described on "The Drive" podcast as driven by frustration with reactive medicine's inability to prevent the chronic diseases he saw killing his patients [1].

From the OR to the Lab

Attia's surgical residency gave him direct exposure to the consequences of metabolic disease. Pancreatic cancer cases, cardiovascular events on the table, diabetic complications requiring amputation. He has stated publicly that watching patients arrive "too late" shaped his decision to leave surgery [1]. His time at the NCI (approximately 2009 to 2011) refined his quantitative thinking, a skill set he later applied to self-tracking and n-of-1 experiments.

The McKinsey Interlude

Before and briefly after medical school at Stanford, Attia worked as a management consultant at McKinsey & Company. That analytical background shows up in his communication style: dense, data-forward, and structured around frameworks rather than anecdotes. He has referenced this training as the origin of his emphasis on "first principles" reasoning in clinical decision-making [2].

2011 to 2014: The Ketogenic and Self-Experimentation Phase

Attia's earliest public presence revolved around aggressive metabolic self-experimentation. He adopted a strict ketogenic diet around 2011 and maintained it for roughly three years. During this period he also pursued ultra-endurance cycling, including open-water swimming from Catalina Island.

Nutritional Ketosis Advocacy

He co-founded the Nutrition Science Initiative (NuSI) in 2012 alongside Gary Taubes, a nonprofit aimed at funding rigorous studies on low-carbohydrate diets and the carbohydrate-insulin model of obesity. NuSI commissioned a controlled feeding study led by Kevin Hall at the NIH, published in 2016 in the American Journal of Clinical Nutrition (N=17), which found that a ketogenic diet did not produce a statistically significant increase in body fat loss compared to a high-carbohydrate diet matched for protein and calories [3]. The result challenged the strong version of the carbohydrate-insulin hypothesis Attia had been promoting.

Shifting Away from Keto

By approximately 2014 to 2015, Attia began publicly stepping back from strict ketosis. He described the shift on multiple podcast appearances as prompted by performance limitations and evolving interpretation of the metabolic literature. He has since settled on a higher-protein, moderate-carbohydrate approach, though he still uses continuous glucose monitoring to personalize carbohydrate tolerance. This willingness to reverse a publicly held position is unusual among health influencers and has been noted by physicians such as Layne Norton, PhD, who called Attia "one of the few people in this space who actually updates his priors when the data change" [4].

2015 to 2019: Building the Longevity Framework

This period marks Attia's transition from metabolic N=1 experimenter to systematic longevity clinician. He founded his concierge medical practice (originally called Early Medical, later operating as Attia Medical PC) and began publishing detailed content on what he termed "Medicine 3.0."

The Four Pillars of Exercise

Attia's exercise framework crystallized during this period into four categories: stability, strength, aerobic efficiency, and anaerobic output. He has disclosed training roughly 10 to 12 hours per week, split across zone 2 cardio (typically cycling or rucking), heavy compound lifts, dedicated stability work (often DNS-based or Pilates-inspired), and VO2 max intervals [5].

A 2022 retrospective cohort study published in JAMA Network Open (N=750,302) found that cardiorespiratory fitness was inversely associated with all-cause mortality, with the most fit group (top 2.3%) showing a hazard ratio of 0.20 (95% CI 0.16 to 0.24) compared to the least fit [6]. Attia has cited this study repeatedly as foundational evidence for his emphasis on VO2 max as the single strongest predictor of longevity.

Pharmacology Enters the Public Record

Between 2017 and 2019, Attia began disclosing specific pharmacological interventions on his podcast. These included:

• Rapamycin (sirolimus): Attia has described taking rapamycin at a pulsed weekly dose (he has mentioned 5 to 6 mg once weekly, with periodic breaks). His rationale centers on mTOR pathway modulation and preclinical lifespan extension data, including the NIA Interventions Testing Program (ITP), which found that rapamycin extended median lifespan by 9% in male mice and 14% in female mice [7].
• Metformin: He initially took metformin based on observational data suggesting reduced cancer incidence and all-cause mortality in diabetic populations. He later discontinued it after the MASTERS trial (N=94), published in Aging Cell in 2019, showed that metformin blunted the hypertrophic response to resistance training in older adults [8].
• Testosterone replacement therapy (TRT): Attia has confirmed being on TRT, though he has not publicly specified his exact protocol or dosing. He has framed this as a clinical decision made in the context of verified low testosterone levels.

2020 to 2023: "Outlive" and Mainstream Recognition

Attia's profile expanded dramatically with the 2023 publication of Outlive: The Science and Art of Longevity, co-authored with Bill Gifford. The book debuted at number one on the New York Times bestseller list and sold over one million copies in its first year.

The Book's Core Thesis

Outlive argues that modern medicine operates in a "Medicine 2.0" approach, reacting to disease after it has declared itself. Attia's "Medicine 3.0" proposes intervening decades earlier, using biomarkers, imaging (coronary CT angiography, DEXA scans), and aggressive risk-factor management to delay the onset of what he calls the "Four Horsemen": atherosclerotic cardiovascular disease, cancer, neurodegenerative disease, and metabolic dysfunction [9].

The Emotional Health Chapter

One of the most discussed sections of Outlive describes Attia's experience with severe emotional detachment and the near-dissolution of his marriage. He entered a residential program at The Bridge to Recovery and subsequently underwent dialectical behavior therapy (DBT). He has stated in interviews that "the fifth component of longevity, emotional health, is the one most likely to determine whether the other four are even worth pursuing" [9]. This disclosure surprised many followers who had associated Attia primarily with biochemistry and metrics.

Clinical Practice Evolution

By 2023, Attia Medical PC operated as a concierge practice charging annual fees reportedly in the range of $100,000 to $150,000. Patients receive extensive baseline testing including advanced lipid panels (Lp(a), apoB, LDL-P), coronary artery calcium scoring, whole-body MRI, DEXA, VO2 max testing, and continuous glucose monitoring. The Endocrine Society's 2020 clinical practice guideline recommends apoB measurement as "a more accurate marker of atherogenic risk than LDL-C" in discordant patients [10], consistent with the apoB-first approach Attia advocates.

What Does Peter Attia Take? His Disclosed Protocol

Attia has discussed his personal protocol across multiple episodes of "The Drive" and in print. His disclosed stack, as of his most recent public statements, includes the following categories.

Prescription Medications

• Rapamycin (sirolimus): Pulsed dosing, approximately 5 to 6 mg weekly. He has described periodic "drug holidays" and monitoring via CBC and metabolic panels. A 2014 paper by Mannick et al. In Science Translational Medicine (N=218) showed that a rapamycin analog (everolimus) at low doses improved immune function in elderly subjects, with a 20% improvement in influenza vaccine response [11].
• Testosterone replacement therapy: Confirmed but dosing undisclosed.
• Baby aspirin: Attia has mentioned taking low-dose aspirin (81 mg) for cardiovascular risk reduction, though he has noted that the ASPREE trial (N=19,114) complicated the risk-benefit calculus for primary prevention in healthy older adults, showing no significant reduction in cardiovascular events (HR 0.95, 95% CI 0.83 to 1.08) [12].
• Statin or PCSK9 inhibitor: He has described pursuing aggressive apoB lowering but has not consistently named the specific agent.

Supplements

Attia has disclosed the following supplements at various points, though he emphasizes that his stack changes:

• EPA/DHA (high-dose fish oil, approximately 2 g EPA per day)
• Vitamin D3 (targeting serum levels of 40 to 60 ng/mL)
• Magnesium (multiple forms, including L-threonate for sleep)
• Methylfolate and methyl-B12
• AG1 (Athletic Greens, a sponsorship-disclosed relationship)

What He Stopped Taking

The metformin discontinuation is well documented. He stopped after reviewing the MASTERS trial data showing blunted muscle protein synthesis with concurrent resistance training [8]. He has also described discontinuing various supplements over time based on updated bloodwork or lack of measurable effect.

Attia's Influence on Longevity Medicine

Attia's reach extends beyond his practice. His podcast, "The Drive," has hosted physicians and researchers including Rhonda Patrick, PhD; David Sinclair, PhD; and Steven Austad, PhD, among many others. The long-form interview format (episodes often exceed two hours) has created a large library of clinical education content that other physicians reference.

Pushing apoB Into the Mainstream

One of Attia's most measurable impacts has been popularizing apolipoprotein B (apoB) as a primary cardiovascular risk marker. Before his advocacy (beginning around 2018 to 2019), apoB testing was uncommon outside lipidology practices. The European Atherosclerosis Society and European Society of Cardiology's 2019 dyslipidemia guidelines recommend apoB measurement as a secondary target, particularly when LDL-C and apoB are discordant, noting that "apoB provides a better estimate of the atherogenic particle concentration" [13]. Allan Sniderman, MD, a McGill cardiologist who has studied apoB for decades, has stated that "Peter Attia probably did more to bring apoB into routine clinical consciousness than any single published paper" [14].

Criticisms and Limitations

Attia's approach is not without critics. The high cost of his concierge practice limits accessibility. Several of his pharmacological choices (rapamycin for non-transplant use, TRT without published testosterone values) lack Phase III trial support in healthy populations. A 2023 editorial in The Lancet Healthy Longevity cautioned that "the enthusiasm for rapamycin in human longevity outpaces the clinical evidence, which remains largely preclinical or limited to short-term biomarker studies" [15].

His exercise recommendations, while grounded in epidemiological data, demand a time commitment (10+ hours weekly) that is impractical for most working adults. He has acknowledged this on his podcast, stating that "the dose I'm taking is probably more than necessary, and the minimum effective dose is likely much lower" [5].

Timeline Summary

| Year(s) | Event | |---|---| | 2003 to 2008 | General surgery residency, Johns Hopkins | | 2009 to 2011 | NCI research fellowship, quantitative immunotherapy | | ~2011 | Begins strict ketogenic diet, ultra-endurance training | | 2012 | Co-founds NuSI with Gary Taubes | | ~2014 to 2015 | Exits strict keto, adopts moderate-carb approach | | ~2015 to 2016 | Founds Early Medical (concierge longevity practice) | | 2017 to 2019 | Begins disclosing rapamycin, metformin, TRT use publicly | | 2018 | Launches "The Drive" podcast | | 2019 | Discontinues metformin after MASTERS trial data | | 2020 to 2021 | Completes DBT, discusses emotional health publicly | | March 2023 | Outlive published, #1 NYT bestseller | | 2024 | "The Drive" surpasses 100 million downloads |

How to Evaluate Attia's Protocol for Yourself

Attia himself has repeatedly warned against copying his protocol. His recommendations are made in the context of his own lab values, imaging, genetics, and risk tolerance. Any individual considering rapamycin, TRT, or aggressive lipid-lowering should work with a physician who can interpret their specific data.

Minimum Actionable Steps From the Evidence

The interventions with the strongest population-level evidence from Attia's framework are not pharmacological. Zone 2 cardiovascular training (three to four sessions per week, 30 to 45 minutes), resistance training (two to three sessions per week), sleep optimization (seven to nine hours, per the American Academy of Sleep Medicine's 2015 consensus recommendation) [16], and apoB measurement as part of routine lipid screening represent the highest-yield, lowest-risk starting points.

The Endocrine Society recommends screening for testosterone deficiency only in men with consistent symptoms (fatigue, low libido, reduced muscle mass) and confirmed low morning total testosterone on at least two occasions (<300 ng/dL), not as a routine longevity intervention [17].